Literature DB >> 21460232

Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Matthew Rosebraugh1, John A Widness, Peter Veng-Pedersen.   

Abstract

The primary objective of this work was to determine the optimal time for administration of an erythropoietin (Epo) dose to maximize the erythropoietic effect using a simulation study based on a young sheep pharmacodynamic model. The dosing optimization was accomplished by extending a Hb production pharmacodynamic model, which evaluates the complex dynamic changes in the Epo receptor (EpoR) pool from the changes in Epo clearance. Fourteen healthy 2-month-old sheep were phlebotomized to Hb levels of 3 to 4 g/dl. Epo clearance was evaluated longitudinally in each animal by administering tracer doses of (125)I-recombinant human Epo multiple times during the experiment. Kinetic parameters were estimated by simultaneously fitting to Hb data and Epo clearance data. The phlebotomy caused a rapid temporary increase in the endogenous Epo plasma level. The Hb began to increase after the increased in the Epo level with a lag time of 1.13 ± 0.79 days. The average correlation coefficients for the fit of the model to the Hb and clearance data were 0.953 ± 0.018 and 0.876 ± 0.077, respectively. A simulation study was done in each sheep with fixed individual estimated model parameters to determine the optimal time to administer a 100 U/kg intravenous bolus Epo dose. The optimal dose administration time was 11.4 ± 6.2 days after phlebotomy. This study suggests that the Hb produced from Epo administration can be optimized by considering the dynamic changes in the EpoR pool.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460232      PMCID: PMC3127239          DOI: 10.1124/dmd.110.036855

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  42 in total

1.  Pharmacokinetics and distribution of recombinant erythropoietin in rats.

Authors:  H Kinoshita; N Ohishi; M Kato; S Tokura; A Okazaki
Journal:  Arzneimittelforschung       Date:  1992-02

2.  The metabolism of recombinant erythropoietin in the isolated perfused rat liver.

Authors:  O J Nielsen; M Egfjord; P Hirth
Journal:  Liver       Date:  1990-12

Review 3.  Intracellular pathways and mechanisms of sorting in receptor-mediated endocytosis.

Authors:  V L Shepherd
Journal:  Trends Pharmacol Sci       Date:  1989-11       Impact factor: 14.819

4.  The in vivo metabolism of recombinant human erythropoietin in the rat.

Authors:  J L Spivak; B B Hogans
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

5.  Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells.

Authors:  S T Sawyer; S B Krantz; E Goldwasser
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

6.  Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure.

Authors:  T Salmonson; B G Danielson; A Grahnén; B Wikström
Journal:  J Intern Med       Date:  1990-07       Impact factor: 8.989

7.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

8.  Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin.

Authors:  Y Beguin; G K Clemons; P Pootrakul; G Fillet
Journal:  Blood       Date:  1993-02-15       Impact factor: 22.113

9.  Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.

Authors:  D Kampf; K U Eckardt; H C Fischer; C Schmalisch; B Ehmer; M Schostak
Journal:  Nephron       Date:  1992       Impact factor: 2.847

10.  A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies.

Authors:  J A Widness; R L Schmidt; P Veng-Pedersen; N B Modi; S T Sawyer
Journal:  J Lab Clin Med       Date:  1992-03
View more
  2 in total

1.  A Novel Combination Therapy of Erythropoietin and Thrombopoietin to Treat Erythropoietin-Resistance anemia.

Authors:  Huixi Zou; Peng Xu; Raymond S M Wong; Xiaoyu Yan
Journal:  Pharm Res       Date:  2022-06-03       Impact factor: 4.200

2.  Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Gretchen Cress; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2013-11-11       Impact factor: 3.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.